<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2025-6340</article-id><article-id custom-type="edn" pub-id-type="custom">HQWBFJ</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-6340</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОБЛЕМНАЯ СТАТЬЯ</subject></subj-group></article-categories><title-group><article-title>Сегодня липитензия – завтра катастрофа: фокус на пожилых коморбидных больных</article-title><trans-title-group xml:lang="en"><trans-title>Lipitension today — disaster tomorrow: focus on elderly comorbid patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8856-3638</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скотников</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Skotnikov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К. м. н., доцент кафедры медико-социальной экспертизы, неотложной и поликлинической терапии, к.м.н., доцент, зав. кафедрой фармакологии и клинической фармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">skotnikov.as@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4027-3727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Закиев</surname><given-names>В. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakiev</surname><given-names>V. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>М.н.с. лаборатории изучения геропротекторов и клинических исследований</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5684-9842</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гвоздева</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Gvozdeva</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К.м.н., н.с. </p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6932-0729</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бектемирова</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bektemirova</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-терапевт</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский университет);&#13;
ФГБОУ ВО Российский государственный социальный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University;&#13;
Russian State Social University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова (Пироговский университет) Минздрава России, ОСП Российский геронтологический научно-клинический центр</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University, Russian Gerontology Research and Clinical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ Московский многопрофильный научно-клинический центр им. С. П. Боткина ДЗМ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Botkin Multidisciplinary Research and Clinical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФКУЗ Главный клинический госпиталь МВД РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Main Clinical Hospital of the Ministry of Internal Affairs</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2025</year></pub-date><volume>30</volume><issue>4</issue><fpage>6340</fpage><lpage>6340</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Скотников А.С., Закиев В.Д., Гвоздева А.Д., Бектемирова Л.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Скотников А.С., Закиев В.Д., Гвоздева А.Д., Бектемирова Л.Г.</copyright-holder><copyright-holder xml:lang="en">Skotnikov A.S., Zakiev V.D., Gvozdeva A.D., Bektemirova L.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/6340">https://russjcardiol.elpub.ru/jour/article/view/6340</self-uri><abstract><p>У пациентов в пожилом и старческом возрасте часто встречается сочетание артериальной гипертензии и атерогенной дислипидемии, которые как по отдельности, так и в сочетании ("липитензия") ассоциированы с высоким риском сердечно-сосудистых осложнений. В клинической практике важен не просто сам возраст, а наличие у пациентов гериатрических синдромов, в частности, синдрома старческой астении, который характеризуется высоким риском развития неблагоприятных исходов для здоровья и смерти, а также потери автономности. В настоящей статье представлены актуальные данные об эффективности и безопасности антигипертензивной и гиполипидемической терапии у пожилых пациентов, а также обсуждается тезис, согласно которому регулярный приём многоцелевых политаблеток, содержащих в себе фиксированную комбинацию амлодипина, периндоприла и аторвастатина, позволяет повысить приверженность к терапии, а также обеспечить баланс между эффективностью и безопасностью лечения пожилых коморбидных пациентов с рядом гериатрических синдромов, терапия которых традиционно связана с вынужденной полипрагмазией и бесконтрольным приёмом лекарственных препаратов.</p></abstract><trans-abstract xml:lang="en"><p>In elderly and senile patients, a combination of hypertension and atherogenic dyslipidemia is often encountered, which, both separately and in combination ("lipitension"), are associated with a high risk of cardiovascular events. In clinical practice, it is not just the age itself that is important, but the presence of geriatric syndromes in patients. In particular, frailty is characterized by a high risk of adverse outcomes and death, as well as loss of autonomy. This article presents current data on the efficacy and safety of antihypertensive and lipidlowering therapy in elderly patients. It also discusses the thesis that fixed-dose combination of amlodipine, perindopril and atorvastatin can increase adherence to therapy and ensure a balance between the efficacy and safety of treatment in elderly comorbid patients with a number of geriatric syndromes. The treatment of such patients is traditionally associated with polypharmacy and uncontrolled use of medications.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>коморбидность</kwd><kwd>липитензия</kwd><kwd>пожилой и старческий возраст</kwd><kwd>старческая астения</kwd><kwd>полипрагмазия</kwd><kwd>многоцелевая политаблетка</kwd></kwd-group><kwd-group xml:lang="en"><kwd>comorbidity</kwd><kwd>lipitension</kwd><kwd>elderly and senile age</kwd><kwd>frailty</kwd><kwd>polypharmacy</kwd><kwd>multi-purpose polypill.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8): 1003-10. doi:10.1001/jama.287.8.1003.</mixed-citation><mixed-citation xml:lang="en">Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8): 1003-10. doi:10.1001/jama.287.8.1003.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020;75(2):285-92. doi:10.1161/HYPERTENSIONAHA.119.14240.</mixed-citation><mixed-citation xml:lang="en">Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020;75(2):285-92. doi:10.1161/HYPERTENSIONAHA.119.14240.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dalal JJ, Padmanabhan TN, Jain P, et al. Lipitension: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2):240-5. doi:10.4103/22308210.93742.</mixed-citation><mixed-citation xml:lang="en">Dalal JJ, Padmanabhan TN, Jain P, et al. Lipitension: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2):240-5. doi:10.4103/22308210.93742.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006; 98(2):204-8. doi:10.1016/j.amjcard.2006.01.079.</mixed-citation><mixed-citation xml:lang="en">Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006; 98(2):204-8. doi:10.1016/j.amjcard.2006.01.079.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wong ND, Lopez VA, Roberts CS, et al. Combined association of lipids and blood pressure in relation to incident cardiovascular disease in the elderly: the cardiovascular health study. Am J Hypertens. 2010;23(2):161-7. doi:10.1038/ajh.2009.216.</mixed-citation><mixed-citation xml:lang="en">Wong ND, Lopez VA, Roberts CS, et al. Combined association of lipids and blood pressure in relation to incident cardiovascular disease in the elderly: the cardiovascular health study. Am J Hypertens. 2010;23(2):161-7. doi:10.1038/ajh.2009.216.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bernard I.Symposium on hypertension in the elderly: should we treat hypertension in the elderly? Age and Ageing. 1979;8(2):115-20. doi:10.1093/ageing/8.2.115.</mixed-citation><mixed-citation xml:lang="en">Bernard I.Symposium on hypertension in the elderly: should we treat hypertension in the elderly? Age and Ageing. 1979;8(2):115-20. doi:10.1093/ageing/8.2.115.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-54.</mixed-citation><mixed-citation xml:lang="en">Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-54.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145-51. doi:10.1136/bmj.293.6555.1145.</mixed-citation><mixed-citation xml:lang="en">Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145-51. doi:10.1136/bmj.293.6555.1145.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.</mixed-citation><mixed-citation xml:lang="en">Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-5. doi:10.1016/0140-6736(91)92589-t.</mixed-citation><mixed-citation xml:lang="en">Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-5. doi:10.1016/0140-6736(91)92589-t.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14(10):1237-45. doi:10.1097/00004872-199610000-00013.</mixed-citation><mixed-citation xml:lang="en">Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14(10):1237-45. doi:10.1097/00004872-199610000-00013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачева О. Н., Котовская Ю.В., Рунихина Н.К. и др. Клинические рекомендации "Старческая астения". Российский журнал гериатрической медицины. 2025;(1):6-48. doi:10.37586/2686-8636-1-2025-6-48.</mixed-citation><mixed-citation xml:lang="en">Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical Guidelines on Frailty. Russian Journal of Geriatric Medicine. 2025;(1):6-48. (In Russ.) doi:10.37586/2686-8636-1-2025-6-48.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ji L, Jazwinski SM, Kim S.Frailty and Biological Age. Ann Geriatr Med Res. 2021;25(3): 141-9. doi:10.4235/agmr.21.0080.</mixed-citation><mixed-citation xml:lang="en">Ji L, Jazwinski SM, Kim S.Frailty and Biological Age. Ann Geriatr Med Res. 2021;25(3): 141-9. doi:10.4235/agmr.21.0080.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bai G, Wang Y, Mak JKL, et al. Is Frailty Different in Younger Adults Compared to Old? Prevalence, Characteristics, and Risk Factors of Early-Life and Late-Life Frailty in Samples from Sweden and UK. Gerontology. 2023;69(12):1385-93. doi:10.1159/000534131.</mixed-citation><mixed-citation xml:lang="en">Bai G, Wang Y, Mak JKL, et al. Is Frailty Different in Younger Adults Compared to Old? Prevalence, Characteristics, and Risk Factors of Early-Life and Late-Life Frailty in Samples from Sweden and UK. Gerontology. 2023;69(12):1385-93. doi:10.1159/000534131.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Vetrano DL, Palmer KM, Galluzzo L, et al. Hypertension and frailty: a systematic review and meta-analysis. BMJ Open. 2018;8(12):e024406. doi:10.1136/bmjopen-2018-024406.</mixed-citation><mixed-citation xml:lang="en">Vetrano DL, Palmer KM, Galluzzo L, et al. Hypertension and frailty: a systematic review and meta-analysis. BMJ Open. 2018;8(12):e024406. doi:10.1136/bmjopen-2018-024406.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58(9):1791-6. doi:10.1111/j.1532-5415.2010.03032.x.</mixed-citation><mixed-citation xml:lang="en">Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58(9):1791-6. doi:10.1111/j.1532-5415.2010.03032.x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939.</mixed-citation><mixed-citation xml:lang="en">Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA. 2016;315(24):2673-82. doi:10.1001/jama.2016.7050.</mixed-citation><mixed-citation xml:lang="en">Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA. 2016;315(24):2673-82. doi:10.1001/jama.2016.7050.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-55. doi:10.1016/S0140-6736(24)01028-6.</mixed-citation><mixed-citation xml:lang="en">Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-55. doi:10.1016/S0140-6736(24)01028-6.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-79. doi:10.1056/NEJMoa2111437.</mixed-citation><mixed-citation xml:lang="en">Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-79. doi:10.1056/NEJMoa2111437.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and bloodpressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data metaanalysis. Lancet. 2021;398(10305):1053-64. doi:10.1016/S0140-6736(21)01921-8.</mixed-citation><mixed-citation xml:lang="en">Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and bloodpressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data metaanalysis. Lancet. 2021;398(10305):1053-64. doi:10.1016/S0140-6736(21)01921-8.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.</mixed-citation><mixed-citation xml:lang="en">Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi:10.1093/eurheartj/eht151.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi:10.1093/eurheartj/eht151.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen TN, Harris K, Woodward M, et al. The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial. Diabetes Care. 2021;44(7):1622-19. doi:10.2337/dc20-2664.</mixed-citation><mixed-citation xml:lang="en">Nguyen TN, Harris K, Woodward M, et al. The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial. Diabetes Care. 2021;44(7):1622-19. doi:10.2337/dc20-2664.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. doi:10.1186/s12916-015-0328-1.</mixed-citation><mixed-citation xml:lang="en">Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. doi:10.1186/s12916-015-0328-1.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi:10.1186/1471-2318-8-24.</mixed-citation><mixed-citation xml:lang="en">Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi:10.1186/1471-2318-8-24.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025:ehaf031. doi:10.1093/eurheartj/ehaf031.</mixed-citation><mixed-citation xml:lang="en">McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025:ehaf031. doi:10.1093/eurheartj/ehaf031.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">O'Donoghue P, O'Halloran AM, Kenny RA, Romero-Ortuno R. Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine. 2022;45:101304. doi:10.1016/j.eclinm.2022.</mixed-citation><mixed-citation xml:lang="en">O'Donoghue P, O'Halloran AM, Kenny RA, Romero-Ortuno R. Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine. 2022;45:101304. doi:10.1016/j.eclinm.2022.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Todd OM, Wilkinson C, Hale M, et al. Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing. 2019;48(5):627-35. doi:10.1093/ageing/afz072.</mixed-citation><mixed-citation xml:lang="en">Todd OM, Wilkinson C, Hale M, et al. Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing. 2019;48(5):627-35. doi:10.1093/ageing/afz072.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res. 2019;124(7):1045-60. doi:10.1161/CIRCRESAHA.118.313236.</mixed-citation><mixed-citation xml:lang="en">Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res. 2019;124(7):1045-60. doi:10.1161/CIRCRESAHA.118.313236.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bencivenga L, De Souto Barreto P, Rolland Y, et al. Blood pressure variability: A potential marker of aging. Ageing Res Rev. 2022;80:101677. doi:10.1016/j.arr.2022.101677.</mixed-citation><mixed-citation xml:lang="en">Bencivenga L, De Souto Barreto P, Rolland Y, et al. Blood pressure variability: A potential marker of aging. Ageing Res Rev. 2022;80:101677. doi:10.1016/j.arr.2022.101677.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Chowdhury EK, Nelson MR, Wing LMH, et al. Second Australian National Blood Pressure Study Change in Blood Pressure Variability Among Treated Elderly Hypertensive Patients and Its Association With Mortality. J Am Heart Assoc. 2019;8(21):e012630. doi:10.1161/JAHA.119.012630.</mixed-citation><mixed-citation xml:lang="en">Chowdhury EK, Nelson MR, Wing LMH, et al. Second Australian National Blood Pressure Study Change in Blood Pressure Variability Among Treated Elderly Hypertensive Patients and Its Association With Mortality. J Am Heart Assoc. 2019;8(21):e012630. doi:10.1161/JAHA.119.012630.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Nardin C, Rattazzi M, Pauletto P. Blood Pressure Variability and Therapeutic Implications in Hypertension and Cardiovascular Diseases. High Blood Press Cardiovasc Prev. 2019; 26(5):353-9. doi:10.1007/s40292-019-00339-z.</mixed-citation><mixed-citation xml:lang="en">Nardin C, Rattazzi M, Pauletto P. Blood Pressure Variability and Therapeutic Implications in Hypertension and Cardiovascular Diseases. High Blood Press Cardiovasc Prev. 2019; 26(5):353-9. doi:10.1007/s40292-019-00339-z.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.</mixed-citation><mixed-citation xml:lang="en">Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469-80. doi:10.1016/S1474-4422(10)70066-1.</mixed-citation><mixed-citation xml:lang="en">Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469-80. doi:10.1016/S1474-4422(10)70066-1.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta A, Whiteley WN, Godec T, et al. Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. Eur Heart J. 2024;45(13):1159-69. doi:10.1093/eurheartj/ehad814.</mixed-citation><mixed-citation xml:lang="en">Gupta A, Whiteley WN, Godec T, et al. Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. Eur Heart J. 2024;45(13):1159-69. doi:10.1093/eurheartj/ehad814.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Chang TI, Reboussin DM, Chertow GM, et al. Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2017;70(4):751-8. doi:10.1161/HYPERTENSIONAHA.117.09788.</mixed-citation><mixed-citation xml:lang="en">Chang TI, Reboussin DM, Chertow GM, et al. Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2017;70(4):751-8. doi:10.1161/HYPERTENSIONAHA.117.09788.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Глезер М.Г. Антигипертензивный эффект при переводе на фиксированную комбинацию периндоприл/амлодипин при неэффективности терапии свободными комбинациями, содержащими сартаны. Результаты исследования АВАНГАРД. Кардиология. 2019;59(10):31-8. doi:10.18087/cardio.2019.10.n731.</mixed-citation><mixed-citation xml:lang="en">Glezer MG. Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study. Kardiologiia. 2019;59(10):31-8. (In Russ.) doi:10.18087/cardio.2019.10.n731.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.</mixed-citation><mixed-citation xml:lang="en">Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-15. doi:10.1016/S0140-6736(18)31942-1.</mixed-citation><mixed-citation xml:lang="en">Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-15. doi:10.1016/S0140-6736(18)31942-1.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Bao A, Karalis DG. Statin Therapy for Primary and Secondary Prevention in Older Adults. Curr Atheroscler Rep. 2024;27(1):11. doi:10.1007/s11883-024-01257-9.</mixed-citation><mixed-citation xml:lang="en">Bao A, Karalis DG. Statin Therapy for Primary and Secondary Prevention in Older Adults. Curr Atheroscler Rep. 2024;27(1):11. doi:10.1007/s11883-024-01257-9.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364): 1149-58. doi:10.1016/S0140-6736(03)12948-0.</mixed-citation><mixed-citation xml:lang="en">Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364): 1149-58. doi:10.1016/S0140-6736(03)12948-0.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Collier DJ, Poulter NR, Dahlöf B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens. 2011;29(3):592-9. doi:10.1097/HJH.0b013e328342c8f7.</mixed-citation><mixed-citation xml:lang="en">Collier DJ, Poulter NR, Dahlöf B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens. 2011;29(3):592-9. doi:10.1097/HJH.0b013e328342c8f7.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. doi:10.1016/S0140-6736(04)16895-5.</mixed-citation><mixed-citation xml:lang="en">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. doi:10.1016/S0140-6736(04)16895-5.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29(11):2378-84. doi:10.2337/dc06-0872.</mixed-citation><mixed-citation xml:lang="en">Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29(11):2378-84. doi:10.2337/dc06-0872.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346): 1623-30. doi:10.1016/s0140-6736(02)11600-x.</mixed-citation><mixed-citation xml:lang="en">Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346): 1623-30. doi:10.1016/s0140-6736(02)11600-x.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Z, Ofori-Asenso R, Curtis AJ, et al. Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. J Am Coll Cardiol. 2020;76(1):17-27. doi:10.1016/j.jacc.2020.05.016.</mixed-citation><mixed-citation xml:lang="en">Zhou Z, Ofori-Asenso R, Curtis AJ, et al. Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. J Am Coll Cardiol. 2020;76(1):17-27. doi:10.1016/j.jacc.2020.05.016.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8. doi:10.1002/pds.1287.</mixed-citation><mixed-citation xml:lang="en">Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8. doi:10.1002/pds.1287.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Z, Albarqouni L, Curtis AJ, et al. The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging. 2020;37(3):175-85. doi:10.1007/s40266-019-00736-y.</mixed-citation><mixed-citation xml:lang="en">Zhou Z, Albarqouni L, Curtis AJ, et al. The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging. 2020;37(3):175-85. doi:10.1007/s40266-019-00736-y.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363-71. doi:10.1111/bcp.12687.</mixed-citation><mixed-citation xml:lang="en">Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363-71. doi:10.1111/bcp.12687.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Nanna MG, Navar AM, Wang TY, et al. Statin Use and Adverse Effects Among Adults &gt;75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018;7(10):e008546. doi:10.1161/JAHA. 118.008546.</mixed-citation><mixed-citation xml:lang="en">Nanna MG, Navar AM, Wang TY, et al. Statin Use and Adverse Effects Among Adults &gt;75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018;7(10):e008546. doi:10.1161/JAHA. 118.008546.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Котовская Ю.В., Ткачева О. Н., Сергиенко И.В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119-32. doi:10.18087/cardio.2020.6.n1037.</mixed-citation><mixed-citation xml:lang="en">Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32. (In Russ.) doi:10.18087/cardio.2020.6.n1037.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Horodinschi RN, Stanescu AMA, Bratu OG, et al. Treatment with Statins in Elderly Patients. Medicina (Kaunas). 2019;55(11):721. doi:10.3390/medicina55110721.</mixed-citation><mixed-citation xml:lang="en">Horodinschi RN, Stanescu AMA, Bratu OG, et al. Treatment with Statins in Elderly Patients. Medicina (Kaunas). 2019;55(11):721. doi:10.3390/medicina55110721.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Zoungas S, Curtis A, Spark S, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915. doi:10.1136/bmjopen-2022-069915.</mixed-citation><mixed-citation xml:lang="en">Zoungas S, Curtis A, Spark S, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915. doi:10.1136/bmjopen-2022-069915.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Joseph J, Pajewski NM, Dolor RJ, et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023;71(6):1701-13. doi:10.1111/jgs.18312.</mixed-citation><mixed-citation xml:lang="en">Joseph J, Pajewski NM, Dolor RJ, et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023;71(6):1701-13. doi:10.1111/jgs.18312.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
